×
0 0 0 0 0 0 0 0
Stockreport

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency [Reuters]

ARBUTUS BIOPHARMA CORP COMMON (ABUS)  More Company Research Source: Reuters
Last arbutus biopharma corp common earnings: 11/2 04:00 pm Check Earnings Report
PDF BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from ACORN:3106670068 European Medicines Agency | Reuters Reuters Staff 1 Min Read Nov 13 (Reuters) - NASDAQ-NMS:ABUS Arbutus Biopharma Corp * Arbutus’ LNP Licensee Alnylam r [Read more]

IMPACT SNAPSHOT EVENT TIME: ABUS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

-10.30%

ABUS's stock shows significant drop of -10.30% from 6.75-share to 6.05-share since news

EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS